ArticleAntibiotics (Basel, Switzerland)2023
Characterization of
Article in Antibiotics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 25 citations in OpenAlex.
- Landscape of resistance to ceftolozane/tazobactam and ceftazidime/avibactam in strains of Pseudomonas aeruginosa: a genomic approach in strains without selection pressure in a tertiary-care paediatric hospital in Mexico.BMC infectious diseases · 2026Article
- Molecular Insights into Carbapenem Resistance inInternational journal of molecular sciences · 2026Review
- Molecular insights into antimicrobial resistance in human bacterial pathogens: mechanisms, resistance genes, and translational diagnostic applications.Frontiers in microbiology · 2026Review
- Review
- Emergence of carbapenem-resistantMicrobiology spectrum · 2025Article
- Impact of the COVID-19 Pandemic on Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- Clonal Dissemination of Pandrug-ResistantInternational journal of molecular sciences · 2025Article
- Report of High-Risk Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- Emergence of Tigecycline-Nonsusceptible Carbapenem-ResistantPathogens (Basel, Switzerland) · 2025Article
- From soil to surface water: exploring Klebsiella 's clonal lineages and antibiotic resistance odyssey in environmental health.BMC microbiology · 2025Review
- Dissemination of IncQ1 Plasmids Harboring NTEMicroorganisms · 2025Article
- Transcriptomic Insights into Adaptive Strategies ofInfection and drug resistance · 2025Article
- Mobile genetic elements encoding antibiotic resistance genes and virulence genes inFrontiers in microbiology · 2025Review
- Coexistence of plasmid-mediatedMicrobiology spectrum · 2024Article
- Genomic insights into the evolution and mechanisms of carbapenem-resistant hypervirulent Klebsiella pneumoniae co-harboring blaAnnals of clinical microbiology and antimicrobials · 2024Article
- First Detection of International High-RiskTransboundary and emerging diseases · 2024Article
- Characterisation of a Novel Hybrid IncFIIInfection and drug resistance · 2023Article
- Unveiling the genome of a high-risk pandrug-resistant Klebsiella pneumoniae emerging in the Brazilian Amazon Region, 2022.Memorias do Instituto Oswaldo Cruz · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 3 countries.
Funding
Abstract
The most common resistance mechanism to carbapenems is the production of carbapenemases. In 2021, the Pan American Health Organization warned of the emergence and increase in new carbapenemase combinations in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.